Latest Health News

South32 Limited reported a 29% rise in profit for the half year ended December 2025, driven by higher base and precious metals prices and solid operational performance. The company declared a fully-franked interim dividend and maintained its FY26 production guidance, while advancing key projects and managing portfolio transitions.

Viva Leisure Limited has reported a robust 17.6% rise in revenue and a striking 167.8% jump in net profit for the half-year ending December 2025, yet it has chosen not to declare an interim dividend.

Orora Limited reported a robust 32.2% rise in underlying net profit after tax for the half-year ended December 2025, underpinned by strong volume growth in its Cans segment and operational efficiencies across its glass businesses. The company also completed a $227.4 million share buyback in 2025 and announced a fresh $270 million on-market buyback program.

Orora Limited has announced an ordinary unfranked dividend of AUD 0.05 per share for the six months ending December 2025, with a Dividend Reinvestment Plan available to shareholders.

Breville Group Limited has reported a record half-year revenue of AUD 1.1 billion, overcoming US tariff challenges through strategic manufacturing shifts and robust product innovation. The company’s steady profitability and geographic expansion signal a confident growth trajectory.

Breville Group Limited has announced a fully franked ordinary dividend of AUD 0.19 per share for the six months ending December 2025, signaling steady returns for shareholders.

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

Kingsgate Consolidated capped a transformational 2025 with a 344% share price surge and strong cash position, setting ambitious production and exploration targets for 2026.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Seven West Media’s H1 FY26 results align with guidance, showing resilience in a declining TV advertising market and strong digital growth.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.